Drug Trial Radar · NCT07535775
Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Oct 10, 2026
Study completion Mar 20, 2027
Sponsor
- Lead sponsor
- SPH-BIOCAD (HK) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 after Single Subcutaneous Injection in Healthy Chinese Volunteers
Conditions
- Healthy Adult Participants
Interventions
BCD-261Drug
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- proportion of subjects with serious adverse eventsTime frame: 309days
- proportion of subjects with adverse eventsTime frame: 309days
- proportion of subjects with CTCAE grade 3 or higher adverse eventsTime frame: 309days
- proportion of subjects who prematurely withdrew from the study due to adverse events.Time frame: 309days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.